Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Clinical Study of KW-0761 in Patients With CCR4-Positive Adult T-cell Leukemia-Lymphoma.

Next Previous
X
Search
Trial Profile

Phase II Clinical Study of KW-0761 in Patients With CCR4-Positive Adult T-cell Leukemia-Lymphoma.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 09 Nov 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Mogamulizumab (Primary)
  • Indications Adult T-cell leukaemia-lymphoma
  • Focus Pharmacokinetics; Registrational; Therapeutic Use
  • Sponsors Kyowa Hakko Kirin; Kyowa Kirin

    • Most Recent Events

    • 16 Dec 2019 Results assessing population pharmacikinetic modeling by using data from six studies including this study published in the Journal of Clinical Pharmacology.
    • 01 Oct 2017 Results of pooled data from two trial (NCT00920790 and NCT00355472) assessing efficacy of mogamulizumab in patient with relapsed adult T-cell leukemia-lymphoma, were published in the Cancer Science.
    • 07 Jun 2016 Results of two trials (NCT00920790 [n=28] and NCT01626664 [n=47]) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top